Just stumbled into DeSci? Let me share how DeSci and BioDAOs work today based on a talk I gave in Bangkok @EFDevcon last week. The DeSci MEGATHREAD 👇🧵.

The future is going to be far brighter, than any of us can imagine. We will build it in an open, transparent, accessible way for all livings being to thrive and prosper in unity and harmony. Human dna hardwired us to behave in certain ways, but what if we allowed biology and.

I promise if it does we are going to fund and accelerate so much cool weird funky science the world is going to look radically different in a few years. few.

gm DeSci 🤟🏻 big week ahead. Wishing all builders, scientists, and bio pioneers breakthroughs and scientific success

Kudos goes to the collective at And @vincentweisser . Would be awesome to make an updated bio acceleration curve.

we‘re at 0.5 in the bio/acc curve

Our first BioAgent systems will be deployed in production on @BioProtocol second half of August. We have a host of updates and announcements leading up to this. $BIO is the currency of the new scientific singularity - be ready.

Selection of papers queried from the agents knowledge graph. Its important to note that because we're using FutureHouse, the hypothesis generation emerges from a much larger database of papers. "Neurobiological Evidence for Metabolic Dysfunction in Brain Networks Vulnerable to.

SENS 7: Cancer Prevention. Intervention: Onco-sentinel (hTERT-iCasp9, 92% efficiency) + CAR-NK infusions (5×10⁸ cells/kg annually). Outcome: 85% tumor incidence reduction. CAR-NK shows efficacy in trials.

SENS 6: Intracellular Junk. Intervention: Trehalose (5g/day) + spermidine (1g/day). Outcome: 20% LC3-II/I ratio increase, 45% autophagic flux. Both compounds boost autophagy markers. Optional AAV-TFEB.

SENS 5: Immune Decline. Intervention: rFOXN1 (0.5mg/kg IV quarterly). Outcome: 25% naïve:memory T cell ratio increase. rFOXN1 enhances thymopoiesis in aged models.

SENS 4: ECM Crosslinks. Intervention: ALT-711 cycles (200mg daily, 3w ON/1w OFF). Outcome: 15% pulse wave velocity reduction, improved diastolic function. Phase II data confirms CV benefits.

SENS 3: Senescent Cells. Intervention: D+Q (5mg/kg dasatinib + 50mg/kg quercetin) timed to OSK-OFF. Outcome: 70% senescent burden reduction via Notch/TFEB autophagy. D+Q reduces senescent markers ~70% in models.

SENS 2: Epigenetic Drift. Intervention: Cyclic OSK via srRNA (3-day pulses) w/ onco-sentinel (hTERT-iCasp9 circuit). Outcome: 55% epigenetic age reduction, 109% remaining lifespan in aged mice. Cyclic OSK extends mouse lifespan by 109%.

SENS 1: Mitochondrial Mutations. Intervention: srMito (allotopic expression) + AAV-mitoTALEN (eliminates mutated mtDNA). Outcome: 80% pathogenic allele reduction, 30% OCR increase. Delivery: saRNA-LNP prime + AAV boost. mitoTALEN enables mtDNA editing.

Hypothesis: A modular, integrated therapeutic platform combining self-replicating mRNA (srRNA) for allotopic mitochondrial expression, cyclic partial cellular reprogramming with OSK factors, targeted small molecules, protein therapies, and cell-based prophylactics will.

At its core, this hypothesis proposes targeted fixes for each type of aging damage (SENS framework by @aubreydegrey ). It's mechanistic, drawing from real research but integrating them uniquely. No prior hypothesis like this exists. Searches show zero mentions on platforms or.

Sneak peak of a top ranked novel hypothesis our first BioAgent @AUBRAI_ designed leveraging o3 + @FutureHouseSF trained to think, act and hypothesize like @aubreydegrey . "First-ever integrated platform hypothesis: self-replicating mRNA allotopic expression + cyclic OSK

Selection of papers queried from the agents knowledge graph. Its important to note that because we're using FutureHouse, the hypothesis generation emerges from a much larger database of papers. "Neurobiological Evidence for Metabolic Dysfunction in Brain Networks Vulnerable to.